文献速递脑血管病神经重症与神经感染

急性缺血性卒中合并COVID-19患者血管再通治疗的安全性及结局:全球COVID-19卒中登记研究

Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19: The Global COVID-19 Stroke Registry.
PubMed 文献 · Neurology · 2022-11-09

这项回顾性多中心队列研究纳入105个中心共15128例接受静脉溶栓和/或血管内治疗的急性缺血性卒中患者,其中853例(5.6%)合并COVID-19。COVID-19患者症状性颅内出血、症状性蛛网膜下腔出血、24小时死亡和3个月死亡风险均更高,3个月改良Rankin量表分布更差。现有数据无法就血管再通治疗在COVID-19患者中的有效性得出直接结论,也无法为该亚组制定不同的治疗推荐。

要点

  • 合并COVID-19的急性缺血性卒中患者血管再通治疗后症状性颅内出血风险升高(校正OR 1.53,95%CI 1.16-2.01)。
  • 合并COVID-19患者24小时死亡风险升高(OR 2.47,95%CI 1.58-3.86),3个月死亡风险升高(OR 1.88,95%CI 1.52-2.33)。
  • 现有数据无法就血管再通治疗在COVID-19患者中的有效性得出直接结论或制定不同治疗推荐。

核心结论

  • 合并COVID-19的急性缺血性卒中患者接受血管再通治疗后颅内出血并发症和不良临床结局发生率高于同期非COVID-19接受治疗患者。
  • 现有数据无法就血管再通治疗在COVID-19患者中的有效性得出直接结论,也无法为该缺血性卒中亚组制定不同的治疗推荐。
  • 研究结果可考虑用于治疗决策、患者监测和预后判断。

研究设计与样本

  • 回顾性多中心队列研究,纳入2020年3月至2021年6月期间接受静脉溶栓和/或血管内治疗并检测严重急性呼吸综合征冠状病毒2感染的连续急性缺血性卒中患者。
  • 共纳入105个中心的15128例患者,其中853例(5.6%)诊断为COVID-19。
  • 5848例(38.7%)仅接受静脉溶栓,9280例(61.3%)接受血管内治疗(联合或不联合静脉溶栓)。
  • 采用倾向评分加权与多变量回归相结合的双重稳健模型分析COVID-19与颅内出血并发症及临床结局的关联。
  • 按治疗组(仅静脉溶栓和血管内治疗)进行亚组分析;研究注册号ClinicalTrials.gov NCT04895462。

主要发现

  • COVID-19患者症状性颅内出血发生率更高(校正OR 1.53;95%CI 1.16-2.01)。
  • COVID-19患者症状性蛛网膜下腔出血发生率更高(OR 1.80;95%CI 1.20-2.69)。
  • COVID-19患者症状性颅内出血和/或症状性蛛网膜下腔出血复合终点发生率更高(OR 1.56;95%CI 1.23-1.99)。
  • COVID-19患者24小时死亡风险更高(OR 2.47;95%CI 1.58-3.86),3个月死亡风险更高(OR 1.88;95%CI 1.52-2.33)。
  • COVID-19患者3个月改良Rankin量表评分分布向不良方向偏移(OR 1.42;95%CI 1.26-1.60)。

临床怎么用

  • 研究结果可考虑用于合并COVID-19的急性缺血性卒中患者的治疗决策、患者监测和预后判断。
  • 现有数据无法就血管再通治疗在合并COVID-19的急性缺血性卒中患者中的有效性得出直接结论,也无法为该亚组制定不同的治疗推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: COVID-19-related inflammation, endothelial dysfunction, and coagulopathy may increase the bleeding risk and lower the efficacy of revascularization treatments in patients with acute ischemic stroke (AIS). We aimed to evaluate the safety and outcomes of revascularization treatments in patients with AIS and COVID-19. METHODS: This was a retrospective multicenter cohort study of consecutive patients with AIS receiving intravenous thrombolysis (IVT) and/or endovascular treatment (EVT) between March 2020 and June 2021 tested for severe acute respiratory syndrome coronavirus 2 infection. With a doubly robust model combining propensity score weighting and multivariate regression, we studied the association of COVID-19 with intracranial bleeding complications and clinical outcomes. Subgroup analyses were performed according to treatment groups (IVT-only and EVT). RESULTS: Of a total of 15,128 included patients from 105 centers, 853 (5.6%) were diagnosed with COVID-19; of those, 5,848 (38.7%) patients received IVT-only and 9,280 (61.3%) EVT (with or without IVT). Patients with COVID-19 had a higher rate of symptomatic intracerebral hemorrhage (SICH) (adjusted OR 1.53; 95% CI 1.16-2.01), symptomatic subarachnoid hemorrhage (SSAH) (OR 1.80; 95% CI 1.20-2.69), SICH and/or SSAH combined (OR 1.56; 95% CI 1.23-1.99), 24-hour mortality (OR 2.47; 95% CI 1.58-3.86), and 3-month mortality (OR 1.88; 95% CI 1.52-2.33). Patients with COVID-19 also had an unfavorable shift in the distribution of the modified Rankin score at 3 months (OR 1.42; 95% CI 1.26-1.60). DISCUSSION: Patients with AIS and COVID-19 showed higher rates of intracranial bleeding complications and worse clinical outcomes after revascularization treatments than contemporaneous non-COVID-19 patients receiving treatment. Current available data do not allow direct conclusions to be drawn on the effectiveness of revascularization treatments in patients with COVID-19 or to establish different treatment recommendations in this subgroup of patients with ischemic stroke. Our findings can be taken into consideration for treatment decisions, patient monitoring, and establishing prognosis. TRIAL REGISTRATION INFORMATION: The study was registered under ClinicalTrials.gov identifier NCT04895462.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Marto JP, Strambo D, Ntaios G, et al. Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19: The Global COVID-19 Stroke Registry. Neurology. 2022. PMID: 36351814. doi:10.1212/WNL.0000000000201537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。